KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organon (OGN) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Organon (OGN) over the last 6 years, with Q3 2025 value amounting to $672.0 million.

  • Organon's Cash & Equivalents fell 1192.66% to $672.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $672.0 million, marking a year-over-year decrease of 1192.66%. This contributed to the annual value of $675.0 million for FY2024, which is 259.74% down from last year.
  • As of Q3 2025, Organon's Cash & Equivalents stood at $672.0 million, which was down 1192.66% from $599.0 million recorded in Q2 2025.
  • Organon's 5-year Cash & Equivalents high stood at $1.0 billion for Q3 2021, and its period low was $141.0 million during Q1 2021.
  • Over the past 5 years, Organon's median Cash & Equivalents value was $672.0 million (recorded in 2025), while the average stood at $604.6 million.
  • In the last 5 years, Organon's Cash & Equivalents surged by 604166.67% in 2021 and then tumbled by 5049.6% in 2022.
  • Over the past 5 years, Organon's Cash & Equivalents (Quarter) stood at $737.0 million in 2021, then fell by 4.21% to $706.0 million in 2022, then fell by 1.84% to $693.0 million in 2023, then fell by 2.6% to $675.0 million in 2024, then dropped by 0.44% to $672.0 million in 2025.
  • Its Cash & Equivalents stands at $672.0 million for Q3 2025, versus $599.0 million for Q2 2025 and $547.0 million for Q1 2025.